

**From:** [Foka, Ekaterina I.](#)  
**To:** [Director PTABDecision Review](#)  
**Cc:** [msernel@kirkland.com](#); [jmerkin@kirkland.com](#); [egoryunov@kirkland.com](#); [garovas@kirkland.com](#); [arabinowitz@kirkland.com](#); [Apple-PMC-PTAB@kirkland.com](#); [Kline, Douglas J](#); [tscott@pmcip.com](#)  
**Subject:** Notification of Filing: IPR2016-00754 Patent Owner's Request for Director Review  
**Date:** Wednesday, December 8, 2021 3:27:49 PM  
**Attachments:** [image001.png](#)  
[image002.png](#)  
[image003.png](#)  
[image004.png](#)  
[image005.png](#)  
[image006.png](#)  
[01. PMC IPR Appeal --Petition for Director Review \(IPR2016-754, CAFed 20-1197\).pdf](#)  
**Importance:** High

---

**CAUTION:** This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Board:

This email serves as notice of the filing of Patent Owner's Request or Director Review in IPR2016-00754 through the PTAB E2E portal (Paper No. 48) following the procedures outlined in the Arthrex Q&As (FAQ A2). Counsel of record for Patent Owner and Petitioner are included on this email notice.

Respectfully,  
**Ekaterina I. Foka**



Goodwin Procter LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018  
o +1 212 459 7187  
f +1 212 355 3333  
[EFoka@goodwinlaw.com](mailto:EFoka@goodwinlaw.com)



\*\*\*\*\*

This message was sent from Goodwin Procter LLP and is intended only for the designated recipient(s). It may contain confidential or proprietary information and may be subject to the attorney-client privilege or other confidentiality protections. If you are not a designated recipient, you may not review, copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank you.

\*\*\*\*\*